Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis

Clinical and Experimental Allergy

Volumn 32, Issue 10, 2002, Pages 1504-1509

  Wilson, A M ^a   Haggart, K ^a   Sims, E J ^a   Lipworth, B J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Antihistamine; Desloratadine; Fexofenadine; Nasal congestion; Seasonal allergic rhinitis

Indexed keywords

DESLORATADINE; FEXOFENADINE; PLACEBO;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; FEMALE; GRASS POLLEN; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEASONAL VARIATION; SORE THROAT; SYMPTOMATOLOGY; THORAX DISEASE; URINARY FREQUENCY; VOMITING;

ADULT; AIR POLLUTANTS; ALLERGENS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENVIRONMENTAL EXPOSURE; FEMALE; FORCED EXPIRATORY VOLUME; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; LUNG; MALE; POLLEN; RHINITIS, ALLERGIC, SEASONAL; TERFENADINE;

EID: 0036408830     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2745.2002.01509.x     Document Type: Article

References (36)

1. Settipane RA. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc 2001; 22:185-9.
2. Butland BK, Strachan DP, Lewis S, Bynner J, Butler N, Britton J. Investigation into the increase in hay fever and eczema at age 16 observed between the 1958 and 1970 british birth cohorts. BMJ 1997; 315:717-21.
3. Grupp-Phelan J, Lozano P, Fishman P. Health care utilization and cost in children with asthma and selected comorbidities. J Asthma 2001; 38:363-73.
4. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001; 108:S45-S53.
5. Blaiss MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 2000; 21:7-13.
6. Wasserman B. Allergic rhinitis and wellness opportunities. Manag Care Interface 2001; 14:38-45.
7. 1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 1998; 317:1624-9.
8. Durham SR. ABC of Allergies: Summer hay fever. BMJ 1998; 316:843-5.
9. Day J. Pros and cons of the use of antihistamines in managing allergic rhinitis. J Allergy Clin Immunol 1999; 103:S395-S399.
10. Galant SP, Wilkinson R. Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: What are the options? Biodrugs 2001; 15:453-63.
11. Horak F, Stubner P, Zieglmayer R et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. & fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001; 125:73-9.
12. Bousquet J, Van Cauwenberge P, Khaltaev N in collaboration with WHO. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108:S147-S336.
13. Simpson K, Jarvis B. Fexofenadine: A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000; 59:301-21.
14. McClellan K, Jarvis B. Desloratadine. Drugs 2001; 61:789-96.
15. Gupta S, Banfield C, Kantesaria B, Marino M, Clement R, Affrime M. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: A randomized, placebo-controlled, parallel-group study. Clin Ther 2001; 23:451-66.
16. Mann RD, Pearce LG, Dunn N, Shakir S, Ferner RE. Sedation with 'non-sedating' antihistamines: Four prescription-event monitoring studies in general practice Commentary: Reporting of adverse events is worth the effort. BMJ 2000; 320:1184-7.
17. Prenner BM, Capano D, Harris AG. Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: A double-blind comparison with crossover treatment of nonresponders. Clin Ther 2000; 22:760-9.
18. Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000; 30:891-9.
19. Wilson AM, Orr LC, Coutie WJ, Sims EJ, Lipworth BJ. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32:126-32.
20. Geha RS, Meltzer EO. Desloratadine: A new, non-sedating, oral antihistamine. J Allergy Clin Immunol 2001; 107:751-62.
21. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2000; 85:1114.
22. Wilson AM, Sims EJ, Orr LC et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87:344-9.
23. Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79:443-8.
24. ronsky EA, Falliers CJ, Kaiser HB, Ahlbrandt R, Mason JM. Effectiveness and safety of fexofenadine, a new nonsedating Hireceptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc 1998; 19:135-41.
25. Horak F, Stubner P, Zieglmayer R et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. & fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001; 125:73-9.
26. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Doubleblind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104:927-33.
27. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001; 56 (Suppl. 65):21-7.
28. Meltzer EO, Casale TB, Nathan RA, Thompson AK. Once-daily fexofenadine HCL improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1999; 83:311-7.
29. Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001; 56 (Suppl. 65): 14-20.
30. Ciprandi G, Cosentino C, Milanese M, Mondino C, Canonica GW. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001; 56:1068-70
31. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001; 56:1077-80.
32. Paolieri F, Battifora M, Riccio AM, et al. Terfenadine and fexofenadine reduce in vitro ICM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998; 81:601-7.
33. Papi A, Papadopoulos NG, Stanciu LA, Degitz K, Holgate ST, Johnston SL. Effect of desloratadine and loratadine on rhinovorus-induced intercellular adhesion molecule 1 upregulation and promoter activation inrespiratory epithelial cells. J Allergy Clin Immunol 2001; 108:221-8.
34. Wilson AM, Dempsey OJ, Sims EJ, Coutie WJ, Patterson MC, Lipworth BJ. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak nasal inspiratory flow. Clin Exp Allergy 2000; 30:833-8.
35. Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effects of monotheraphy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001; 31:61-8.
36. Cardelus I, Anton F, Beleta J, Palacios JM. Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle. Eur J Pharmacol 1999; 374:249-54.